Compare PFS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFS | NUVB |
|---|---|---|
| Founded | 1839 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 1.6B |
| IPO Year | 2002 | N/A |
| Metric | PFS | NUVB |
|---|---|---|
| Price | $20.36 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $23.75 | $11.22 |
| AVG Volume (30 Days) | 726.8K | ★ 4.7M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ 112.38 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $73,109,000.00 | N/A |
| Revenue This Year | $0.42 | $182.76 |
| Revenue Next Year | $6.17 | $91.83 |
| P/E Ratio | $9.13 | ★ N/A |
| Revenue Growth | ★ 7.06 | N/A |
| 52 Week Low | $14.34 | $1.57 |
| 52 Week High | $23.98 | $9.75 |
| Indicator | PFS | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 34.56 |
| Support Level | $19.34 | $4.04 |
| Resistance Level | $20.41 | $5.73 |
| Average True Range (ATR) | 0.61 | 0.32 |
| MACD | -0.21 | -0.04 |
| Stochastic Oscillator | 13.58 | 16.38 |
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.